U.S. Markets open in 2 hrs 8 mins

AbbVie Inc. (4AB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
63.472-0.268 (-0.420%)
As of 11:52AM CEST. Market open.
Full screen
Previous Close63.740
Bid63.333 x 60000
Ask63.453 x 60000
Day's Range63.137 - 63.472
52 Week Range50.183 - 66.109
Avg. Volume546
Market Cap106.07B
PE Ratio (TTM)16.45
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • The Wall Street Journal6 hours ago

    [$$] AbbVie Ordered to Pay $150 Million in AndroGel Lawsuit

    A federal-court jury in Chicago ordered drugmaker AbbVie to pay $150 million in punitive damages to an Oregon man after finding the company liable for fraudulent misrepresentations about the safety of ...

  • Reuters15 hours ago

    U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

    A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages. The verdict, which came in response to a lawsuit Jesse Mitchell and his wife filed in 2014, is the first in response to over 6,000 pending lawsuits that have been consolidated in federal court in Chicago. The decision in the Mitchell case is the first in a series of test trials aimed at helping plaintiffs and manufacturers of AndroGel gauge the range of damages and define a legal strategy and settlement options.

  • Why Reata Pharmaceuticals Is Rallying 17.5% Today
    Motley Fool15 hours ago

    Why Reata Pharmaceuticals Is Rallying 17.5% Today

    Trial results showing mid-stage success for a drug targeting a rare form of chronic kidney disease are sparking interest in the clinical-stage biotech stock.